Market Place
Sourcing Support
Merck-Gilead long-acting oral combo suppresses HIV for 48 weeks
22 Oct 2024 //
FIERCE BIOTECH
Gilead Presents Data From PURPOSE 2 Trial At HIV Conference
07 Oct 2024 //
BUSINESSWIRE
Access To HIV Drug Hinges On Waiver Of Local Clinical Trials
03 Oct 2024 //
ECONOMICTIMES
Dr Reddy`s sign voluntary licenses with Gilead for HIV drug
02 Oct 2024 //
PRESS RELEASE
Gilead looks to `redefine` HIV PrEP market of long-acting Sunlenca
09 Aug 2024 //
FIERCE PHARMA
Gilead Presents Full Results Of Lenacapavir For HIV Prevention At AIDS 2024
24 Jul 2024 //
BUSINESSWIRE
Gilead`s long-acting HIV drug superior to daily pill Truvada in study
21 Jun 2024 //
REUTERS
Merck-Gilead`s weekly HIV combo maintains viral suppression
07 Mar 2024 //
FIERCE BIOTECH
Data Presented at EACS 2023 Demonstrate Strong Profile of Twice-Yearly Sunlenca
20 Oct 2023 //
BUSINESSWIRE
Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir
18 Oct 2023 //
BUSINESSWIRE
Twice-Yearly Lenacapavir Shows Sustained Impact on Quality of Life
24 Jul 2023 //
BUSINESSWIRE
Gilead Sciences` Sunlenca (lenacapavir) Approved In Europe
27 Jun 2023 //
EMA
Gilead Presents Data for Combination Regimen of Lenacapavir with Antibodies
22 Feb 2023 //
BUSINESSWIRE
FDA approves Gilead`s long-acting HIV injectable Sunlenca
23 Dec 2022 //
FIERCEPHARMA
FDA Approves New HIV Drug for Adults with Limited Treatment Options
22 Dec 2022 //
PRNEWSWIRE
Gilead`s Sunlenca (Lenacapavir) Receives Approval in Europe
25 Aug 2022 //
EMA
Gilead`s twice-yearly HIV med snags first nod after FDA rebuff
23 Aug 2022 //
FIERCEPHARMA
Four months after CRL, Gilead returns to FDA for next-gen HIV drug
29 Jun 2022 //
ENDPTS
Gilead Resubmits NDA to U.S. FDA for Lenacapavir
27 Jun 2022 //
BUSINESSWIRE
Lenacapavir Receives Positive CHMP Opinion With Multi-Drug Resistant HIV
24 Jun 2022 //
BUSINESSWIRE
Gilead, having resolved manufacturing issues, forges ahead with HIV drug
18 May 2022 //
BIOPHARMADIVE
Gilead Sciences Says FDA Lifts Clinical Hold On Injectable Lenacapavir
17 May 2022 //
MARKETWATCH
U.S. FDA declines to approve Gilead`s HIV drug on glass vial concerns
02 Mar 2022 //
REUTERS
New Clinical Data Support the Sustained Efficacy of Long-acting Lenacapavir
16 Feb 2022 //
BUSINESSWIRE
Gilead`s injectable HIV prospect on hold over particulate fears
23 Dec 2021 //
FIERCEPHARMA
Gilead’s HIV therapy trials placed on clinical hold
22 Dec 2021 //
CLINICALTRIALSARENA
FDA places clinical hold on use of injectable lenacapavir for HIV treatment
22 Dec 2021 //
PHARMAFILE
Gilead Puts Clinical Hold on Studies Evaluating Injectable Lenacapavir for HIV
21 Dec 2021 //
BUSINESSWIRE
Merck pauses 2 more trials of backbone HIV drug over red flag
08 Dec 2021 //
FIERCEBIOTECH
Merck`s islatravir hits with a PhIII combo win; FDA filing plans
26 Oct 2021 //
ENDPTS
Gilead’s lenacapavir prospects strongest in long-acting combos with islatravir
30 Aug 2021 //
CLINICAL TRIAL ARENA
Gilead’s lenacapavir: HIV prospects strongest in long-acting combos islatravir
25 Aug 2021 //
CLINICAL TRAL ARENA
Gilead Submits New Drug Application to U.S. FDA for Lenacapavir
28 Jun 2021 //
BUSINESSWIRE
Gilead’s lenacapavir maintains high virologic suppression rates in trial
10 Mar 2021 //
CLINICALTRIALSARENA
Gilead’s Investigational Lenacapavir Demonstrates Sustained Long-Acting Efficacy
09 Mar 2021 //
BUSINESSWIRE
Gilead`s lenacapavir meets primary goal in multidrug resistant HIV-1
20 Nov 2020 //
PHARMAFILE
Gilead Announces Investigational Long-Acting HIV-1 Capsid Inhibitor, Lenacapavir
18 Nov 2020 //
PRESS RELEASE
